NasdaqGS - Nasdaq Real Time Price • USD
Adaptimmune Therapeutics plc (ADAP)
At close: April 23 at 4:00 PM EDT
After hours: April 23 at 7:41 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 5 | 4 | 5 |
| Avg. Estimate | -0.1 | -0.06 | -0.28 | -0.42 |
| Low Estimate | -0.17 | -0.14 | -0.55 | -0.7 |
| High Estimate | -0.03 | -0.01 | -0.06 | -0.06 |
| Year Ago EPS | 0.01 | -0.12 | -0.54 | -0.28 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 7 | 6 | 7 |
| Avg. Estimate | 10.73M | 25.91M | 75.01M | 56.04M |
| Low Estimate | -- | 4.4M | 22.2M | 21.5M |
| High Estimate | 45M | 38M | 137.3M | 90.7M |
| Year Ago Sales | 47.6M | 5.13M | 60.28M | 75.01M |
| Sales Growth (year/est) | -77.50% | 405.10% | 24.40% | -25.30% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.14 | -0.13 | -0.12 | -0.1 |
| EPS Actual | 0.01 | -0.12 | -0.2 | -0.24 |
| Difference | 0.15 | 0.01 | -0.08 | -0.14 |
| Surprise % | 107.10% | 7.70% | -66.70% | -140.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.1 | -0.06 | -0.28 | -0.42 |
| 7 Days Ago | -0.13 | -0.09 | -0.4 | -0.42 |
| 30 Days Ago | -0.1 | -0.06 | -0.27 | -0.37 |
| 60 Days Ago | -0.14 | -0.14 | -0.49 | -0.61 |
| 90 Days Ago | -0.14 | -0.14 | -0.49 | -0.61 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 1 | 1 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | 1 | -- |
Growth Estimates
| CURRENCY IN USD | ADAP | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -1,100.00% | -- | -- | 0.40% |
| Next Qtr. | 50.00% | -- | -- | 9.90% |
| Current Year | 48.10% | -- | -- | 4.30% |
| Next Year | -50.00% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 1.00% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Barclays: Underweight to Underweight | 8/10/2023 |
| Reiterates | EF Hutton: Buy to Buy | 8/10/2023 |
| Reiterates | EF Hutton: Buy to Buy | 6/5/2023 |
| Reiterates | EF Hutton: Buy | 6/2/2023 |
| Reiterates | EF Hutton: Buy | 5/26/2023 |
| Reiterates | EF Hutton: Buy | 4/17/2023 |
Related Tickers
XFOR X4 Pharmaceuticals, Inc.
1.2300
-9.56%
ABEO Abeona Therapeutics Inc.
3.4100
-53.67%
DAWN Day One Biopharmaceuticals, Inc.
16.64
+8.19%
ADCT ADC Therapeutics SA
4.9700
+6.20%
AFMD Affimed N.V.
5.35
+7.00%
MREO Mereo BioPharma Group plc
2.7800
-0.36%
IOVA Iovance Biotherapeutics, Inc.
11.86
+4.77%
PSTX Poseida Therapeutics, Inc.
2.1600
+0.23%
KPTI Karyopharm Therapeutics Inc.
1.0900
-3.54%
IBRX ImmunityBio, Inc.
5.49
+11.13%